Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coronavirus: AVAT to partner with UNICEF in scaling up vaccine deliveries to African Union Member States

08/03/2021 | 08:15am EDT

Having secured access to up to 400 million doses of the J&J COVID-19 vaccine, the African Union (AU), African Vaccine Acquisition Trust (AVAT) and UNICEF are partnering to ensure the seamless procurement and delivery of vaccines to AU Member States. This partnership will help ramp up efforts to mitigate the impact of the pandemic as less than 2 per cent of people on the continent are fully vaccinated so far.

"We are building a platform for deeper collaboration that will pave the way to a more robust African response to the pandemic and move the continent towards recovery, leveraging the opportunities to strengthen health systems and support the manufacturing sector for job creation," said Dr. Vera Songwe, United Nations Under-Secretary-General and Executive Secretary of the Economic Commission for Africa.

"We are pleased to have UNICEF as a strategic partner in the delivery of these vaccines to our member states, as they are extremely experienced in handling and managing vaccines, and a strong and well-established relationship with all AU member states," said Mr. Strive Masiyiwa, African Union Special Envoy.

Established by African leaders, AVAT has spearheaded African efforts on fair equitable access and distribution of vaccines, negotiating vaccine acquisition with pharmaceutical companies to at least 60 per cent of the African population with safe and efficacious vaccines to achieve "herd immunity" by 2022.

"Since the pandemic began, Africa CDC has worked with COVAX to ensure that African Union Member States get fair access to COVID-19 vaccines. At this critical moment where widespread vaccination is more urgent than ever, we must do all to vaccinate at least 60 per cent of the African population by 2022," said Dr. John Nkengasong, Director of Africa CDC.

The procurement of these vaccine doses has been made possible with the support of the African Export-Import Bank (Afreximbank), which provided a US$2 billion Advance Procurement Commitment (APC) Guarantee facility to Johnson and Johnson on behalf of the AU Member States. The bank also made available direct financing to AU Member States which require funding to pay for the vaccines. In April 2021, Afreximbank made a down payment of US$330 million to Johnson and Johnson on behalf of the AU Member States, as part of the commitment under the Agreement.

"As the Financial and Transaction advisers to AVAT on the Johnson & Johnson Agreement, we are pleased to formally welcome UNICEF to the partnership and look forward to a fruitful collaboration for efficient delivery of vaccines to African countries," said Professor Benedict Oramah, President of Afreximbank.

Access to vaccines is the surest way out of the COVID-19-19 pandemic. Emerging new variants suggest that global recovery will remain elusive if Africa is left behind. Speed and scale in vaccine distribution are imperative for economic recovery. AVAT is pleased to be working with UNICEF to scale up the delivery of the acquired vaccines to countries to quickly increase the number of vaccinated people.

The AVAT and UNICEF partnership will also work to increase procurement and manufacturing on the continent as part of a broader strategy for sustainable health systems and job creation in Africa.

The pandemic has highlighted Africa's pharmaceutical manufacturing vulnerabilities. Prior to the pandemic, the continent was only able to manufacture less than 2 per cent of the total medicines needed.

"Access to COVID-19 vaccines has been unjust and unfair, with people in Africa bearing the brunt of this inequality. This cannot continue," said UNICEF Executive Director Henrietta Fore. "UNICEF is a staunch partner of the African continent with a long history of delivering vaccines everywhere they are needed. We are pleased to join this partnership with the African Union and AVAT to maximize supply and access to vaccines."

The distribution of the J&J vaccines to countries through AVAT Advanced Purchase Agreement is expected to commence in August 2021.

Distributed by APO Group on behalf of United Nations Children's Fund (UNICEF).


(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about JOHNSON & JOHNSON
08:52aARROWHEAD PHARMACEUTICALS : Earns $10 Million Phase 1 Milestone Payment, Based on Agreemen..
08:25aJOHNSON & JOHNSON : - New Phase 3 Data Suggest Positive Effect and Show Similar Safety wit..
08:25aJOHNSON & JOHNSON : John Sisk & Son - Bio Cork 2 named 'International Project of the Year ..
08:11aJOHNSON & JOHNSON : The Janssen Pharmaceutical - New Phase 3 Data Suggest Positive Effect ..
07:52aJOHNSON & JOHNSON : Launches a Health Equity Innovation Challenge in 6 U.S. Cities
07:01aJOHNSON & JOHNSON : Celebrates COVID-19 Vaccine Science Superheroes
09/27JOHNSON & JOHNSON : New Phase 3 Data Suggest Positive Effect and Show Similar Safety with ..
09/27CORONAVIRUS : U.S. Government Donates 336,000 Single-dose Johnson & Johnson Vaccines to Mo..
09/24CORONAVIRUS : U.S. Government Donates 336,000 Single-dose Johnson & Johnson Vaccines to Mo..
09/24JOHNSON & JOHNSON : Pennsylvania Jury Reportedly Finds Johnson & Johnson Baby Power Didn't..
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 18,9x
Yield 2021 2,55%
Capitalization 430 B 430 B -
EV / Sales 2021 4,57x
EV / Sales 2022 4,36x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 163,17 $
Average target price 185,83 $
Spread / Average Target 13,9%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557
ABBVIE INC.0.53%190 360